Furthermore, co-treatment of AMD3100 (a CXCR4 inhibitor) and docetaxel significantly reduces tumor growth in the PC-3 CRPC xenograft mouse model relative to monotherapy and can sensitize PC-3 cells to docetaxel [289]. The gene discussed is CXCR4; the disease is neoplasm.